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EPIDEMIOLOGY AND PREVENTION
Cost-Effectiveness of Frequent HIV Testing of High-Risk
Populations in the United States
Angela B. Hutchinson, PhD, MPH, Paul G. Farnham, PhD, Stephanie L. Sansom, PhD, MPP, MPH,
Emine Yaylali, PhD, and Jonathan H. Mermin, MD
Purpose: Data showing a high incidence of HIV infection among
men who have sex with men (MSM) who had annual testing suggest
that more frequent HIV testing may be warranted. Testing technol-
ogy is also a consideration given the availability of sensitive testing
modalities and the increased use of less-sensitive rapid, point-of-care
antibody tests. We assessed the cost-effectiveness of HIV testing of
MSM and injection drug users (IDUs) at 3- and 6-month intervals
using fourth-generation and rapid tests.
Methods: We used a published mathematical model of HIV
transmission to evaluate testing intervals for each population using
cohorts of 10,000 MSM and IDU. We incorporated HIV trans-
missions averted due to serostatus awareness and viral suppression.
We included costs for HIV testing and treatment initiation, and also
treatment costs saved from averted transmissions.
Results: For MSM, HIV testing was cost saving or cost effective
over a 1-year period for both 6-month compared with annual testing
and quarterly compared with 6-month testing using either test.
Testing IDU every 6 months compared with annually was moder-
ately cost effective over a 1-year period with a fourth-generation test,
while testing with rapid, point-of-care tests or quarterly was not cost
effective. MSM results remained robust in sensitivity analysis,
whereas IDU results were sensitive to changes in HIV incidence
and continuum-of-care parameters. Threshold analyses on costs
suggested that additional implementation costs could be incurred
for more frequent testing for MSM while remaining cost effective.
Conclusions: HIV testing of MSM as frequently as quarterly is
cost effective compared with annual testing, but testing IDU more
frequently than annually is generally not cost effective.
Key Words: HIV testing, test frequency, cost-effectiveness, men
who have sex with men, injection drug users
(J Acquir Immune Defic Syndr 2016;71:323–330)
INTRODUCTION
More than 1.2 million people were living with HIV in
the United States in 2011, among which 14% were undiag-
nosed.1 HIV testing is the cornerstone of national prevention
and care programs. Through diagnosis and antiretroviral
therapy (ART), infected persons benefit from reductions in
morbidity and mortality, and can reduce onward transmission
of HIV through behavior change and viral suppression.2–4
HIV prevalence and incidence in the United States are
highest among gay, bisexual, and other men who have sex with
men (MSM). In 2010, 74% of persons living with HIV were
MSM [67% MSM and 7% MSM/injection drug users (IDUs)]
and 13% were IDU.5 The prevalence of undiagnosed infection
among MSM and IDU was 16% and 7%, respectively.1 HIV
incidence is also rising among MSM; among a large sample of
MSM tested in the previous 12 months, more than 7% were
newly diagnosed with HIV.6–8 Recent estimates among IDU
show a 4% prevalence of newly diagnosed HIV.6 High rates of
HIV infection among persons tested in the previous 12 months
and high absolute incidence of HIV suggest that testing is not
conducted frequently enough.
Centers for Disease Control and Prevention (CDC)’s
2006 Revised Recommendations for HIV testing in health
care settings call for testing at least annually for high-risk
persons.7 In 2011, CDC suggested that sexually active MSM
could benefit from more frequent HIV testing.8 Furthermore,
since the 2006 guidelines, HIV testing technologies have
become available that detect HIV earlier than previous tests,
thus reducing the window period during, which infection is
undetectable, and increasing the likelihood that frequent
testing will produce earlier diagnoses. Fourth-generation
immunoassays detect the virus’s p24 antigen, and also the
first class of HIV antibodies to appear after infection,
allowing detection of HIV infection during the acute, highly
infectious stage of disease immediately after HIV acquisition
and before HIV antibodies are detectable.9 These fourth-
generation combination Ag/Ab tests can therefore increase
the benefits of testing at more frequent intervals.
Point-of-care rapid HIV antibody tests are commonly
used in the United States because they can be processed
outside a laboratory and provide test results in 30 minutes.
However, they are typically more expensive and less sensitive
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than conventional, fourth-generation combination Ag/Ab tests
because they have a longer window period of detection, which
may lead to false-negative results for persons with early HIV
infection.10 Conventional tests typically require a return visit
for HIV test results, thus resulting in lower rates of notification
of results. The first fourth-generation, Ag/Ab rapid HIV test
approved by the Food and Drug Administration has recently
been approved for point-of-care use.11,12 In this article, the term
“rapid test” refers to antibody-only test, “fourth-generation
test” refers to conventional fourth-generation Ag/Ab test and
“fourth-generation rapid HIV tests” refers to the fourth-
generation rapid, point-of-care Ag/Ab test.
Two US studies that assessed costs and population
effects of testing for acute HIV infection concluded that testing
MSM and IDU every 6 months with a fourth-generation test
could be cost effective.13,14 Significant gaps in our understand-
ing of the cost-effectiveness of increasing HIV testing
frequency in high-risk populations remain including the role
of test sensitivity and rapid, point-of-care tests. Additionally,
the incremental cost-effectiveness of testing every 3 months
compared with testing every 6 months, and annual testing has
not been evaluated, and no studies have considered additional
costs that may be incurred to facilitate the uptake of increasing
testing frequency. Our objective was to assess the incremental
cost-effectiveness of testing MSM and IDU every 6 months
versus annually and quarterly compared with every 6 months
with conventional, fourth-generation and point-of-care rapid
tests and to investigate circumstances under which frequent
testing is cost effective.
METHODS
Analytic Approach
We modified a previously published model of HIV
transmission to incorporate HIV detection by testing technol-
ogy and frequency.15,16 The HIV Detection and Transmission
model is a Microsoft Excel-based model that uses Visual
Basic Applications to estimate cases of HIV infection
detected and one generation of averted secondary trans-
missions based on the differences in transmission due to
awareness of infection, disease stage (acute versus nonacute
infection), and viral load suppression from earlier ART
initiation. We applied our model to separate, theoretical
cohorts of 10,000 MSM and IDU. We estimated the
additional HIV infections detected and the resulting HIV
transmissions averted for each testing frequency (6-month
versus annual testing and 3-month versus 6-month testing)
and technology (conventional fourth-generation versus point-
of-care rapid testing).
HIV Detection and Transmission
We assumed that all diagnosed infections were new
infections, the incidence rate was constant, there was no
migration of persons into or out of the model, and that testing
occurred on day 90 (quarterly testing) or 180 (testing every 6
months). We estimated the number of new HIV infections
expected for each testing frequency using incidence estimates.
We then used test window periods to assess the probability
infection that was detectable during each testing interval
(Table 1). We assumed that infections that occurred during
the window period would be detected during the subsequent
testing interval. We applied notification rates of 80% for
conventional, fourth-generation testing and 99% for rapid
point-of-care testing.17 For acute infections, we assumed
a 7-day time to receipt of results after a fourth-generation
test and immediate results for rapid, point-of-care testing. We
then estimated the number of HIV infections detected and
duration of awareness of HIV diagnosis for each testing
frequency. Averted transmissions were limited to the period
of earlier awareness of HIV diagnosis conferred by more
frequent testing (eg, 6 months for annual testing). We did not
incorporate the clinical benefits or quality-adjusted life years
(QALY) of earlier diagnosis to the index case for the 3- to
6-month period of earlier awareness of infection because of
more frequent testing. Additional information can be
found in the Appendix (see Supplemental Digital Content,
http://links.lww.com/QAI/A746).
HIV Transmission
We used transmission rates derived from a Bernoulli
model to estimate averted transmissions.18 Transmission rates
were based on awareness of HIV status, the presence of acute
infection, and viral load suppression (acute unaware, acute
aware, established unaware, established aware, established
aware, and suppressed aware) (Table 1). We assumed that
ART is initiated within 3 months of diagnosis that viral
suppression confers a 96% reduction in sexual transmission,
and behavior changes associated with awareness of HIV
positive status confer a 53% reduction in sexual transmission
and varied those parameters in sensitivity analysis.2,3 We
applied CDC surveillance data on the proportion of prevalent
cases with viral suppression, 42.0% MSM and 36.0% IDU, to
newly diagnosed persons.19,20
Annual Incidence Rate
We calculated annual HIV incidence rates for MSM
and IDU as
Annual HIV  Incidence ¼ Number   of   new  cases
Suspectible  population
:
For MSM, we calculated an annual HIV incidence rate of
1.27% (range: 0.99%–1.62%) based on 95% confidence
limits for 2009 HIV incidence and variation in estimates of
the susceptible population.21,22 For IDU, the annual incidence
rate estimate was 0.62% (0.02%–1.2%) based on 2009 HIV
incidence and recent estimates of the IDU population.23,24
Cost-Effectiveness Analysis
We applied HIV testing and treatment costs and
estimated cost per QALY saved for testing every 3 and 6
months compared with annual testing. We used a 1-year time
horizon, adjusted all costs and effects to 2012 dollars, and
Hutchinson et al J Acquir Immune Defic Syndr  Volume 71, Number 3, March 1, 2016
324 | www.jaids.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
discounted any future costs and effects at a 3% annual rate.
We calculated the incremental cost-effectiveness ratio
(ICER), which compares cost and outcomes of each HIV




where C is the total program cost, A is the number of HIV
infections averted, T is the HIV treatment cost saved per
infection averted, and Q is the number of QALY saved per
infection averted.25
HIV Testing and Treatment Costs
Our HIV testing costs represent testing in clinical
settings (Table 1). Costs included laboratory costs, costs for
specimen collection and disclosure of results and also costs
for client recruitment and outreach that we assume would be
required to implement more frequent testing.26–30 For all
persons newly diagnosed with HIV, we included treatment
costs for the period of earlier detection from diagnosis until
the time when annual testing would have occurred. To value
averted HIV transmissions, we used lifetime treatment costs
of $417,000 discounted to the time of infection31 and
evaluated an alternate estimate in sensitivity analysis.32
Scenario Analysis
We modeled a scenario in which a fourth-generation
point-of-care, rapid test was used. Based on test performance
data, we assumed that such a test would have a window
period similar to third-generation HIV tests (22 days), cost
20% more than the current point-of-care rapid tests, and allow
99% of persons to receive their results.33
Sensitivity Analyses
We conducted one-way sensitivity analysis for the
range of values for HIV incidence, test window periods for
fourth-generation tests, receipt of HIV test results for fourth-
generation tests, lifetime HIV treatment costs, and the
reduction in transmission because of awareness of positive
HIV status and viral load suppression (Table 1).
We conducted 2-way sensitivity analyses pairing high-
est and lowest values for reduction in HIV transmission due
TABLE 1. Parameter Values
Parameter Value (Range) Source
Annual HIV incidence rate
MSM 1.27% (0.99%–1.62%) Calculated from Refs. 21,22
IDU 0.62% (0.21%–1.27%) Refs. 23,24
HIV transmission, annual rate (no. transmissions per
person per year)
Acute unaware MSM 1.146; IDU 0.327 Calculated from Refs. 18
Acute aware MSM 0.330; IDU 0.094
Established unaware MSM 0.121; IDU 0.060
Established aware, not suppressed MSM 0.069; IDU 0.037
Established aware, suppressed MSM 0.003; IDU 0.011
HIV cost per test and per-person treatment costs (2012,
USD)
Rapid HIV2, HIV + $22.62; $98.32 Refs. 26,27,29
Fourth-generation IA HIV2; HIV + $10.84; $73.51 Ref. 28
Client recruitment + outreach $16.07 Ref. 30
Lifetime HIV treatment costs $417,000 ($229,800) Refs. 31,32
Annual treatment costs $16,318 Ref. 44
QALY saved per infection averted 4.45 Ref. 31
Testing effectiveness
Fourth-generation IA window period 16 (13–28) d Refs. 45,46
Rapid test window period 54 d Refs. 45–47
Proportion suppressed, IDU 36% (25%–75%) Ref. 20
Proportion suppressed, MSM 42% (25%–75%) Ref. 19
Receipt of results conventional fourth generation IA 80% (40%–100%) Ref. 17
Receipt of results rapid 99% Ref. 17
Reduction in transmission, awareness of HIV
infection
53% (25%–75%) Ref. 2
Reduction in transmission, viral suppression 96% (70%–99%) Refs. 3,48,49
Time to receipt of results, fourth-generation IA 7 d Assumption
IDU, injection drug user.
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to viral suppression (70%–99%) and the probability of viral
suppression among diagnosed persons (25%–75%) (Table 1).
We also conducted threshold analyses to determine how
much program costs could increase under each testing
scenario and still remain, or become, cost effective at the
$100,000 per QALY saved threshold.
RESULTS
For our cohort of MSM, increasing testing frequency to
every 6 months compared with annual testing averted 2.00
and 1.75 HIV transmissions with a conventional fourth-
generation or rapid test, respectively, over a 1-year period and
was cost saving (Table 2). Compared with a strategy of
testing every 6 months, testing quarterly averted an additional
1.20 transmissions and was cost saving with a fourth-
generation test and averted an additional 0.91 HIV trans-
missions with an ICER of $48,000 per QALY saved for rapid
testing. For IDU, increasing testing to every 6 months
compared with annually averted 0.39 HIV transmissions over
1 year with an ICER of $133,200 per QALY for fourth-
generation tests and 0.35 HIV transmissions averted with an
ICER of $232,500 saved for rapid testing. For IDU,
a quarterly testing strategy compared with testing every 6
months yielded 0.21 and 0.15 HIV transmissions averted,
respectively, for fourth-generation testing and rapid testing
with ICERs greater $375,000 and $900,000 per QALY.
Scenario Analysis
For MSM, the use of a fourth-generation, point-of-care
rapid test would be less favorable than conventional,
laboratory-based fourth-generation testing although ICERs
remained cost saving for semiannual testing and $34,700 per
QALY saved for quarterly testing. For IDU, ICERs for
a fourth-generation, point-of-care rapid test would be slightly
more favorable than conventional rapid testing with an ICER
of $204,600 per QALY saved for testing every 6 months and
greater than $700,000 for quarterly testing (data not shown).
Sensitivity Analyses
For MSM, our results were robust and remained cost
saving in all cases of semiannual testing and most cases of
quarterly testing to variations in the value of the fourth-
generation test window period, notification of HIV test
results, viral suppression, and the transmission benefit of
awareness of positive HIV status (data not shown). When we
applied lifetime treatment costs of $229,800, ICERs for
fourth-generation testing were less than $15,000 per QALY
for semiannual and quarterly testing. For quarterly rapid
testing of MSM, results were sensitive to HIV incidence, the
proportion of positives with viral suppression and lower
lifetime treatment costs with ICERs near $100,000 per QALY
at the lower bound and cost saving at the upper bound
(0.99%–1.62% HIV incidence and 25%–75% suppression).
The cost-effectiveness of more frequent testing was
sensitive to a number of parameter variations for IDU with
semiannual testing (Fig. 1). The range of values of HIV
incidence among IDU (0.21%–1.27%) yielded ICERs less
than $100,000 per QALY saved at the highest incidence, and
for the lowest incidence, $400,000 and $700,000 for fourth-
generation and rapid testing, respectively. The most favorable
values for receipt of results (100%) and the proportion
suppressed (75%) resulted in ICERs less than $100,000 per
QALY saved for fourth-generation testing. Our results were

























2.00 519,000 833,800 8.90 259,600 Cost saving —
Fourth-generation
every 3 mo
3.20 (1.20) 349,500 499,200 5.33 292,000 — Cost saving
Rapid every 6 mo 1.75 625,000 728,800 7.78 357,600 Cost saving —
Rapid every 3 mo 2.66 (0.91) 575,400 380,600 4.06 630,300 — 48,000
IDU
Fourth-generation
IA every 6 mo
0.39 390,000 161,000 1.72 1,009,800 133,200 —
Fourth-generation
IA every 3 mo
0.60 (0.21) 447,000 89,100 0.95 2092.500 — 376,500
Rapid every 6 mo 0.35 502,000 144,200 1.54 1,451,500 232,500 —
Rapid every 3 mo 0.50 (0.15) 677,800 63,200 0.67 4,468,900 — 910,600
Fourth-generation refers to conventional tests.
*HIV infections averted are from the given interval compared with annual testing.
†Incremental costs and QALY are calculated for testing every 6 months versus annually for testing every 6 and 3 months versus 6 months for testing every 3 months.
ICERs ¼ ½DC2DðATÞ =DðAQÞ:
ICER, incremental cost per quality-adjusted life year gained.
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not sensitive to changes in the window period for fourth-
generation HIV tests or changes in the reduction in HIV
transmission (25%–75%) related to behavior change for
persons aware of their HIV infection. For quarterly testing,
only the upper bound of IDU incidence produced an ICER
less than $100,000 per QALY saved (data not shown).
In 2-way sensitivity analyses of viral suppression
parameters, we combined the least optimistic values for
MSM and the most optimistic values for IDU (reduction in
HIV transmission due to suppression 70% or 99%, proportion
suppressed 25% or 75%) given our base case findings. Our
results remained robust for MSM for fourth-generation testing
at both 6-month and quarterly testing intervals; however, for
quarterly rapid testing of MSM, the least optimistic viral
suppression parameters resulted in ICERs greater than
$200,000 per QALY saved (Table 3). For IDU, the ICERs
for semiannual testing became more attractive and less than
$100,000 per QALY for fourth-generation testing with
optimistic viral suppression parameters, whereas the ICERs
remained above $200,000 per QALY for quarterly testing
(Table 3).
Threshold Analyses
In threshold analyses of MSM testing frequencies,
testing costs could increase substantially from base case
values and still remain cost effective at a $100,000 per QALY
threshold (Table 4). For testing at 6-month intervals, costs
could increase from $27 to $135 for a fourth-generation and
from $39 to $116 for a rapid test and still remain cost
effective. Quarterly testing would remain cost effective with
costs in the $50–$60 range for fourth-generation and rapid
testing. For IDU, costs for fourth-generation tests would have
to drop 10% to $21% and 50% to $13 to be cost effective for
6-month and quarterly testing, respectively. Testing costs
would have to drop by over one-third for rapid testing to be
cost effective for IDU.
DISCUSSION
Testing MSM at 3-month and 6-month intervals was
cost effective even with the less-sensitive rapid test, whereas
for IDU, testing at the lowest testing frequency evaluated
(every 6 months) combined with a more sensitive (fourth-
generation) test was moderately cost effective.
Testing MSM as frequently as every 3 months was very
cost effective or cost saving under almost all scenarios
evaluated. Although we did not consider targeting to high-
risk MSM such as young MSM or African American MSM,
our sensitivity analyses suggest that such an approach would
FIGURE 1. Tornado Diagrams of one-way
sensitivity analyses of the cost-effectiveness of
semiannual rapid and fourth-generation HIV
testing for IDU. The horizontal bar shows the
range in cost-effectiveness ($ per QALY saved),
given the variation in model parameters and
the parameter values explored in sensitivity
analyses. The vertical line shows the base case
cost-effectiveness. The legend shows base case
parameter values. 4G, fourth-generation HIV
test.
TABLE 3. Two-Way Sensitivity Analysis on Reduction in
Transmission due to Viral Suppression and Proportion
Suppressed











Cost saving Cost saving
MSM rapid, transmission









reduction of VLS 99%,
proportion suppressed 75%
153,500 328,200
Base case values: transmission reduction of VLS 96%, proportion suppressed: 36%
IDU, 42% MSM.
VLS, viral suppression.
TABLE 4. Threshold Analyses of HIV Testing Program Costs for











MSM 4 G, 6 mo 27, 89 135, 410 400%
MSM 4 G, quarterly 27, 89 58, 170 50%
MSM rapid, 6 mo 39, 114 116, 343 200%
MSM rapid, quarterly 39, 114 48, 147 25%
IDU 4 G, 6 mo 27, 89 21, 72 (10%)
IDU 4 G, quarterly 27, 89 13, 45 (50%)
IDU rapid, 6 mo 39, 114 15, 45 (40%)
IDU rapid, quarterly 39, 114 11, 29 (30%)
*HIV testing program costs include all testing and outreach costs.
†From base case value; (), decreases.
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result in cost savings.22 Cost savings are rarely achieved for
health interventions. Thus, more frequent testing for MSM
compares favorably to widely used interventions such as
annual mammography at $61,000 per QALY saved and
diabetes prevention at $31,500 per QALY saved.34,35
Semiannual testing of IDUs could be cost effective
using a laboratory-based, fourth-generation test, whereas
testing with a point-of-care, rapid test was not cost effective.
Quarterly testing of IDUs was also not cost effective.
Integrating testing with services such as drug abuse treatment
may be a good option if more frequent testing is to be
undertaken.36 Lower HIV incidence among IDU compared
with MSM was a major driver, the difference in our cost-
effectiveness results. Declining rates in annual testing among
IDU are also a consideration; recent data from the National
HIV Behavioral Surveillance System show a decline (from
66% to 49%) in testing in the past 12 months among IDU.6,37
Thus, there is a need to balance the benefits of investing in
increased annual testing of IDU with investing in testing IDU
more frequently than annually.
Because additional costs will likely be required to have
clients accept testing at more frequent intervals, we included
in our base case costs ($16) for client recruitment and
outreach, which have not been considered in previous
studies.30 In addition, our threshold analysis showed that for
MSM, $77–$108 per person could be added to the cost of
semiannual testing, and $9–$31 per person could be added to
the cost of quarterly testing while remaining cost effective at
the $100,000 per QALY saved threshold. These additional
costs could be applied to efforts to increase outreach such as
mobile van testing at $21 per person ($2012), to cover costs
associated with increased testing volumes or enhance linkage
services.30 In contrast, for IDU, the only plausible scenario
below the $100,000 per QALY saved threshold occurred if
per-person costs of testing with a fourth-generation test
decreased by $6 and $14 for semiannual and quarterly testing,
respectively. This leaves no room for spending on mobile
vans or other methods to increase testing uptake and capacity,
which reduces the feasibility of frequent testing in this hard-
to-reach population.
Testing method is an important consideration for
increasing testing frequency. In a survey of MSM in
Australia, respondents indicated a willingness to test fre-
quently if testing were rapid, nonclinic-based, and used saliva
or finger stick.38 In the United States, the rapid antibody test
currently surpasses conventional tests as a proportion of the
2.5 million tests annually funded by CDC due to its easier use
outside the clinical setting.17 The ability to provide rapid,
point-of-care testing to people at higher risk than testing in
a clinical setting may also improve cost-effectiveness ratios.
The trade-off with rapid antibody testing, nearly 100%
notification of results but lower test sensitivity, resulted in
fewer averted transmissions compared with a fourth-
generation test at the same testing frequencies. However,
higher rapid testing costs resulted in higher ICERs. Our
scenario analysis indicated that a fourth-generation, point-of-
care rapid test was more cost effective than rapid antibody
tests, although not as attractive as a fourth-generation
laboratory-based test due to slightly lower sensitivity and
higher costs. Nonetheless, there are wide variations in HIV
test costs, and the entrance of a fourth-generation, point-of-
care rapid test into the marketplace may result in changes in
relative prices of HIV testing technologies, ultimately making
cost-effectiveness difficult to predict.28
Our costs were calculated based on the HIV testing
algorithm that has been in place since 1989. However, the
CDC has updated laboratory testing guidelines for the
diagnosis of HIV; the new testing algorithm uses more
sensitive screening (fourth-generation) and confirmatory tests
to facilitate detection of acute and early infection.39 Costs for
the new algorithm are generally estimated to be lower than the
1989 algorithm.28 Additionally, frequent testing increases the
proportion of persons diagnosed with acute and early
infection; thus using the new algorithm is likely to improve
cost-effectiveness.
Our study is subject to several limitations. We did not
consider benefits to the index client because of earlier
diagnosis and treatment initiation. Two randomized clinical
trials have recently provided clear evidence that early ART
improves clinical outcomes compared with delayed ART.40,41
However, the clinical benefits of the treatment for the short 3-
to 6-month period of earlier detection afforded by greater
testing frequency are unknown at this time. We also did not
incorporate the effect of partner notification or serosorting,
both of which could increase the cost-effectiveness of testing
by reducing the likelihood of HIV transmission. Additionally,
we did not consider home tests, which could promote uptake
of more frequent testing or, because of lower test sensitivity,
could increase the rate of false-negative test results and delay
linkage to care.42 We also limited our analysis to a first
generation of transmissions, which could underestimate cost-
effectiveness, particularly in high-risk populations. Our use of
a 96% transmission reduction for persons with a suppressed
viral load, which was obtained from a randomized controlled
trail conducted in stable heterosexual partnerships who used
condoms, may overestimate the true population-level benefit
in MSM and IDU with various levels of adherence.3
However, this is offset by limiting this benefit to the period
of early detection due to more frequent testing. Although we
incorporated the benefits of acute phase detection, we did not
account for early infection, the period up to 90 days after
infection during which viremia is also heightened, which
could underestimate cost-effectiveness. We made the simpli-
fying assumption that all diagnosed infections are incident
infections, which may underestimate cost-effectiveness
because we do not consider the benefits (transmissions
averted) of identifying previously diagnosed persons who
may be relinked to care. We also assumed that timing of
testing did not vary over the 3- or 6-month testing interval. If
there were variation, it could impact the likelihood that testing
occurred during the window period and the duration of
serostatus awareness. Finally, the lifetime treatment costs we
used to value averted transmissions represent costs for
persons receiving optimal HIV care and thus may over-
estimate the costs and the benefit of testing for those who do
not receive that level of care. Nevertheless, the “net effect” of
the potential sources of bias and even sensitivity analyses do
not suggest the findings lean in one direction or the other.
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Our findings are generally consistent with other studies
that have applied different modeling approaches—dynamic
compartmental modeling and mathematical optimization
modeling.13,14,43 Long reported an ICER of $18,000 per
QALY saved for semiannual, fourth-generation testing of
MSM, which is in line with our cost savings results. Key
differences in the Long study compared with ours include
higher test and counseling costs and lower estimated inci-
dence among MSM. Our findings for quarterly testing of
MSM also seem to be in line with a cost-benefit analysis that
found the optimal frequency for high-risk persons is quarterly
testing.43 Compared with Cipriano et al, our findings were
less favorable, although still moderately cost effective
($133,000 versus $30,000 per QALY saved) for semiannual,
fourth-generation testing of IDU. A key difference is that
Cipriano et al used a drug treatment center setting and
assumed 100% of infected IDUs received their HIV test
results, whereas we assumed 80% of results were received.
Other factors that can account for differences in these studies
include differences in model structure and type and also time
horizon (20 years in the dynamic compartmental models
versus 1 year in our study).
We explicitly compared increased testing frequency
with currently recommended annual testing. This comparison
is important to policy makers and program managers who
often need to consider near-term differences in testing
outcomes. We also considered the most common testing
method, rapid antibody testing, which was not as cost
effective as laboratory-based testing. And although the full
costs of increasing testing frequency among these high-risk
groups remains unknown, we addressed a question important
to many policy makers, “How much can be spent on
implementation and still be cost effective?”
In summary, we found that compared with annual
testing, it was cost effective to test MSM as frequently as
every 3–6 months even with increased investment in testing
recruitment and implementation. More frequent than annual
testing of IDU was generally not cost effective for
most IDU.
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